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Jerzy Swierkot17, Alfons A. den Broeder18, Salvatore De Vita9, Eva Rabing
Brix Petersen19, Yang Li8,20, Miguel A. Ferrer3, Alejandro Escudero21, Mihai G. Netea8,22,
Marieke J. H. Coenen23, Vibeke Andersen9,10,24, João E. Fonseca25,26, Manuel Jurado1,2,3,
Katarzyna Bogunia-Kubik27, Eduardo Collantes21 and Juan Sainz1,2,3,28*
1 Genomic Oncology Area, Centre for Genomics and Oncological Research (GENYO), Parque tecnológico de la Salud (PTS)
Granada, Granada, Spain, 2 Hematology Department, Virgen de las Nieves University Hospital, Granada, Spain, 3 Instituto de
Investigación Biosanitaria (IBs) Granada, Granada, Spain, 4 Department of Rheumatology, Virgen de las Nieves University
Hospital, Granada, Spain, 5 Immunology Department, Virgen de las Nieves University Hospital, Granada, Spain, 6 EpiDoC Unit,
CEDOC, NOVA Medical School and National School of Public Health, Universidade Nova de Lisboa, Lisbon, Portugal,
7 Comprehensive Health Research Center (CHRC), NOVA Medical School, Lisbon, Portugal, 8 Department of Internal Medicine
and Radboud Center for Infectious Diseases, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands,
9 Department of Medical Area, Clinic of Rheumatology, University of Udine, Udine, Italy, 10 Molecular Diagnostic and Clinical
Research Unit, IRS-Center Sonderjylland, University Hospital of Southern Jutland, Aabenraa, Denmark, 11 Institute of Molecular
Medicine, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark, 12 The Danish Rheumatologic
Biobank and Copenhagen Center for Arthritis Research (DANBIO) Registry, The Danish Rheumatologic Biobank and
Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and
Orthopaedics, Rigshospitalet, Glostrup, Denmark, 13 Department of Clinical Medicine, Faculty of Health and Medical Sciences,
University of Copenhagen, Copenhagen, Denmark, 14 Rheumatology Department, University of Medicine and Pharmacy “Iuliu
Hatieganu”, Cluj-Napoca, Romania, 15 Rheumatology Unit, University Hospital of Santiago de Compostela, Santiago de
Compostela, Spain, 16 Clinical Analysis Department, Santa Lucı́a University Hospital, Cartagena, Spain, 17 Department of
Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland, 18 Radboud Institute for Health Sciences,
Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 19 Department of Biochemistry and
Immunology, University Hospital of Southern Jutland, Aabenraa, Denmark, 20 Centre for Individualised Infection Medicine (CiiM)
& Centre for Experimental and Clinical Infection Research (TWINCORE), Helmholtz-Centre for Infection Research (HZI) and The
Hannover Medical School (MHH), Hannover, Germany, 21 Rheumatology Department, Reina Sofı́a Hospital/Instituto Maimónides
de Investigación Biomédica de Córdoba (IMIBIC)/University of Córdoba, Córdoba, Spain, 22 Department for Immunology &
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We aimed to validate the association of 28 GWAS-identified genetic variants for response
to TNF inhibitors (TNFi) in a discovery cohort of 1361 rheumatoid arthritis (RA) patients
monitored in routine care and ascertained through the REPAIR consortium and DANBIO
registry. We genotyped selected markers and evaluated their association with response toorg October 2021 | Volume 12 | Article 6722551
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(DDAS28). Next, we confirmed the most interesting results through meta-analysis of our
data with those from the DREAM cohort that included 706 RA patients treated with TNFi.
The meta-analysis of the discovery cohort and DREAM registry including 2067 RA
patients revealed an overall association of the LINC02549rs7767069 SNP with a lower
improvement in DAS28 that remained significant after correction for multiple testing (per-
allele ORMeta=0.83, PMeta=0.000077; PHet=0.61). In addition, we found that each copy of
the LRRC55rs717117G allele was significantly associated with lower improvement in DAS28
in rheumatoid factor (RF)-positive patients (per-allele ORMeta=0.67, P=0.00058;
PHet=0.06) whereas an opposite but not significant effect was detected in RF-negative
subjects (per-allele ORMeta=1.38, P=0.10; PHet=0.45; PInteraction=0.00028). Interestingly,
although the identified associations did not survive multiple testing correction, the meta-
analysis also showed overall and RF-specific associations for the MAFBrs6071980 and
CNTN5rs1813443 SNPs with decreased changes in DAS28 (per-allele ORMeta_rs6071980 =
0.85, P=0.0059; PHet=0.63 and ORMeta_rs1813443_RF+=0.81, P=0.0059; PHet=0.69 and
ORMeta_rs1813443_RF-=1.00, P=0.99; PHet=0.12; PInteraction=0.032). Mechanistically, we
found that subjects carrying the LINC02549rs7767069T allele had significantly increased
numbers of CD45RO+CD45RA+ T cells (P=0.000025) whereas carriers of the
LINC02549rs7767069T/T genotype showed significantly increased levels of soluble
scavengers CD5 and CD6 in serum (P=0.00037 and P=0.00041). In addition, carriers
of the LRRC55rs717117G allele showed decreased production of IL6 after stimulation of
PBMCs with B burgdorferi and E coli bacteria (P=0.00046 and P=0.00044), which
suggested a reduced IL6-mediated anti-inflammatory effect of this marker to worsen
the response to TNFi. In conclusion, this study confirmed the influence of the LINC02549
and LRRC55 loci to determine the response to TNFi in RA patients and suggested a weak
effect of the MAFB and CNTN5 loci that need to be further investigated.Keywords: GWAS, genetic variant, rheumatoid arthritis, drug response, TNF inhibitorsINTRODUCTION
Rheumatoid Arthritis (RA) is a complex and chronic disease
marked by symptoms of inflammation and pain in the joints
that eventually lead to joint destruction, loss of function and
disability. These symptoms of inflammation are mostly driven
by certain central cytokines that modulate both cellular and
humoral immune responses in the synovial fluid and synovium
of patients (1). Although RA remains as a chronic and
incurable autoimmune disease that occurs in as much as 0.5-
1% of the general population (2), the introduction of biological
agents to target deregulated cytokines has substantially
improved the signs and symptoms of the disease (3). Among
these cytokines, tumor necrosis factor alpha (TNFa) has
attracted most attention as it has been found to be
deregulated in patients with autoimmune diseases including
RA (4). It has been reported, for instance, that TNFa activates
macrophages, synoviocytes, chondrocytes, and osteoclasts
in a dose-dependent manner (5) and that high levels of
circulating TNFa correlate with disease activity and disease
progression (6).org 2The increasing number of biological agents approved by the
FDA and the increased prevalence of the disease all around the
world (7) have placed a substantial economic burden for health
care systems. Although the introduction of biosimilars in clinical
practice reduced the cost of these treatments in many countries
(8), there is still an unmet need to optimize biologic therapies,
avoiding unnecessary adverse effects risks and reducing costs (9).
The interplay between genetics and drug response has been
the subject of intense investigations during last decades.
Response to biologics has been shown to vary between
individuals and that a large proportion of patients show no
clinical improvement (10). Given the high cost of these drugs and
the potential impairment of non-responding patients, the
identification of genetic biomarkers associated with drug
response to specific biological agents would help to know
which patients might benefit from a particular treatment.
However, to date, only a few genome-wide association studies
(GWAS) (11–17) or well powered candidate gene association
studies have been conducted (18–26). We are far from being able
to optimize drug dosing or prioritize drug combinations based
on genetic findings. In fact, attempts to validate the association ofOctober 2021 | Volume 12 | Article 672255
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have failed (27), which confirms the limited application of
genetic findings in a clinical setting. Considering that the
validation of previous GWAS findings is an essential step to
tailor treatments for RA and to approach personalized medicine,
we aimed to validate the association of GWAS-identified variants
for response to TNF inhibitors (TNFi) in a two-stage nested case-
control association study including a cohort of 1361 anti-TNF
naïve RA patients ascertained through the REPAIR consortium
and DANBIO registry and an independent replication cohort of
706 RA patients treated with TNFi from the DREAM registry.
We also investigated whether the effect of selected markers on
the response to TNFi could be modified by rheumatoid factor
(RF) status, and whether genetic variants could influence
immune responses and affect the serological concentration of
108 plasmatic inflammatory proteins, 7 serum steroid hormones
or counts of 91 blood-derived immune cell populations.MATERIAL AND METHODS
Study Populations and Response to TNFi
The discovery population consisted of 1361 RA patients
ascertained through the REPAIR consortium and the DANBIO
registry (Table 1) (28, 29). RA patients fulfilled the 1987 revised
American College of Rheumatology (ACR) (30) and/or the ACR/
EULAR 2010 classification criteria (31). In order to further
replicate the most interesting results, we validated the
association with response to anti-TNF drugs of those SNPs
showing a P<0.05 in the discovery cohort in 706 Dutch RA
patients treated with TNFi from the DREAM (Dutch
RhEumatoid Arthritis Monitoring) registry (Supplementary
Table 1). The study followed the Declaration of Helsinki.
Study participants were of European origin and gave theirFrontiers in Immunology | www.frontiersin.org 3written informed consent to participate in the study, which
was approved by the ethical review committee of participant
institutions: Virgen de las Nieves University Hospital (2012/89);
Santa Maria Hospital-CHLN (CE 877/121.2012); University
Clinical Hospital of Santiago de Compostela (2013/156);
Wroclaw Medical University (KB-625/2016); Radboud
university medical center (2011/299) and by the Regional
Ethics Committee of Central Denmark Region (S-20120113). A
detailed description of the discovery population has been
reported elsewhere (19, 20, 22, 24). All RA patients were naïve
for TNFi and response to TNFi for each patient in all study
populations was calculated using the change in disease activity
score (DAS28CRP) between baseline and 6 months after
treatment. Overall and RF-stratified linear regression analyses
adjusted for age, sex and country of origin were used to
determine the association between GWAS-identified SNPs and
changes in DAS28. RA patients with missing values either for
DAS28 (in at the time points of interest) or RF were not included
in the analysis.
DNA Extraction, SNP Selection,
Genotyping, and Quality Control
Genomic DNA from RA patients was extracted from blood
samples using the QIAamp DNA Blood Mini kit (Valencia,
CA, EEUU) according to manufacturer’s instructions. The
single-nucleotide polymorphisms (SNPs) were selected through
an extensive literature search of relevant GWAS and meta-
analyses published by February 2019 using publicly available
online databases. Additional criteria were potential functionality
and linkage disequilibrium between the reported SNPs.
Biological function was predicted according to the data
publicly available in the integrated Regulome database (www.
regulomedb.org), and eQTL data browsers (www.gtexportal.org/
home/ and https://genenetwork.nl/bloodeqtlbrowser/). A total of
28 SNPs in 25 genes were selected for genotyping in the discovery
cohort (Table 2). Genotyping of selected SNPs was performed
using KASP® probes according to manufacturer’s instructions
(LGC Genomics, Hoddesdon, UK). For quality control, ~5% of
DNA samples were randomly included as duplicates and
concordance between duplicate samples was ≥99.0%.
Replication of the most interesting association was conducted
in the DREAM registry (n=706) following a similar quality
control genotyping strategy.
Hardy-Weinberg Equilibrium, Genetic
Association Analysis, and Meta-Analysis
Deviation from Hardy-Weinberg Equilibrium (HWE) was tested
in the control group (responders and moderate responders
according to the EULAR response criteria) by chi-square (c2),
and linear regression analysis adjusted for age, sex and country of
origin was used to assess the associations of the GWAS-identified
polymorphisms with absolute changes in DAS28 assuming log-
additive, dominant and recessive models of inheritance. Those
SNPs with the lowest P-value in the discovery population
according to each genetic model were advanced for replication
in the DREAM cohort and meta-analysis of the discovery and
replication populations using a fixed effect model was performedTABLE 1 | Demographic and clinical characteristics of anti-TNF patients.
Anti-TNF patients (n=1361)
Demographic characteristics REPAIR consortium + DANBIO
registry
Age (years) 52 ± 14
Sex ratio (female/male) 3.4 (1050/310)
Clinical assessment
Percentage of patients with RF positivity Ϯ 721 (67.45)
Percentage of ACPA-positive patients f 728 (64.03)
DAS28 at baseline 5.91 ± 1.23
Disease duration (years) 12.92 ± 12.90
Treatments
First biologic agent
Infliximab (%) 386 (28.36)
Etanercept (%) 466 (34.24)
Adalimumab (%) 413 (30.35)
Golimumab (%) 48 (03.53)
Certolizumab (%) 67 (04.04)
Biosimilars (%) 16 (01.76)Number of patients (%).
ϮRF status was available for 1069 patients.
fACPA status was available for 1137 patients.October 2021 | Volume 12 | Article 672255
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heterogeneity between studies. Correction for multiple testing
was performed using the Bonferroni method but also considering
the two inheritance models tested. Given that log-additive and
dominant models showed a high degree of collinearity, the
significant threshold for the meta-analysis was set to 0.00089
considering log-additive/dominant and recessive inheritance
models (0.05/28SNPs/2models). Overall statistical power was
calculated using Quanto (v.12.4) assuming a log-additive
model and a baseline risk of 30% for response to TNFi (32, 33).
Cell Isolation, Differentiation and Cytokine
Quantitative Trait Loci, and Hormone
Analysis in Relation to the GWAS-
Identified Variants for Response To TNFi
With the aim of determining whether those SNPs associated with
response to TNFi had a role in modulating immune responses,
we performed in vitro stimulation experiments and measured
cytokine production (IFNg, IL1Ra, IL1b, IL6, IL8, IL10, TNFa,
IL17, and IL22) after stimulation of peripheral blood
mononuclear cells (PBMCs), whole blood or monocyte-derived
macrophages (MDMs) from 408 healthy subjects of the 500FG
cohort from the Human Functional Genomics Project (HFGP)
with LPS (1 or 100 ng/ml), PHA (10mg/ml), Pam3Cys (10mg/ml),
CpG (ODN M362; 10mg/ml) and B. burgdorferi and E. coli, as
experimental model for cytokine production capacity. Given theFrontiers in Immunology | www.frontiersin.org 4sex disparities in the prevalence and course of RA and the impact
of steroid hormones in modulating immune responses, we also
evaluated the correlation of SNPs with serum levels of 7 steroid
hormones (androstenedione, cortisol, 11-deoxy-cortisol, 17-
hydroxy progesterone, progesterone, testosterone and 25
hydroxy vitamin D3) in a subset of the 500FG cohort without
hormonal replacement therapy or oral contraceptives (n=280).
After log transformation, cytokine or serum steroid hormone
levels were correlated with the SNPs of interest using a linear
regression model with age and sex as co-factors in R (http://
www.r-project.org/). This analysis led to cytokine quantitative
trait loci (cQTL) and hormone quantitative trait loci (hQTL).
Significance thresholds were set to be 0.000463 and 0.00357
(0.05/6stimulants/9cytokines or 0.05/7hormones and 2
inheritance models) for cQTL and hQTL, respectively.
Correlation Between GWAS-Identified
Polymorphisms and Cell Counts of 91
Blood-Derived Immune Cell Populations
and Serum/Plasmatic Proteomic Profile
We also investigated whether selected polymorphisms had an
impact on blood cell counts by analyzing a set of 91 manually
annotated immune cell populations and genotype data from the
500FG cohort that consisted of 408 healthy subjects
(Supplementary Table 2). Cell populations were measured by
10-color flow cytometry (Navios flow cytometer, BeckmanTABLE 2 | Selection of GWAS-identified SNPs for response to anti-TNF drugs.
dbSNP rs# Chr. Position (GRCh38.p7) Nearest gene Nucleotide substitution Effect allele SNP location Reference
rs885813 1 21550581 ALPL C/T T Intronic (14)
rs885814 1 21549423 ALPL C/T T Intronic (14)
rs1813443 11 100140279 CNTN5 G/C C Intronic (16)
rs8046065 16 3788297 CREBBP C/T T Intronic (14)
rs6138150 20 23866372 CST2||CST5 C/T C Intergenic (15)
rs6028945 20 40192165 HSPEP1||MAFB G/T T Intergenic (15)
rs6071980 20 40239936 HSPEP1||MAFB C/T C Intergenic (15)
rs3849942 9 27543283 IFNK||C9orf72 T/C T ncRNA (15)
rs13393173 2 168532581 LASS6 A/G A Intronic (15)
rs4411591 18 6550118 LINC01387 C/T A Intronic (16)
rs983332 1 87666697 LMO4||PKN2 A/C A Intergenic (15)
rs1875620 9 88925144 C9orf47||LOC100128660||LOC100128911 A/G A Intergenic (14)
rs1539909 18 71581359 CBLN2||LOC100132647 A/G A Intronic (14)
rs7767069 6 68060671 LOC102723883||LINCO2549 A/T T Downstream (16)
rs1568885 7 13597906 LOC107986770||ETV1 A/T T Intronic (16)
rs10520789 15 95598638 LINC00924 A/G A Downstream (14)
rs11870477 17 69806211 MAP2K6||KCNJ16 A/C C Intronic (14)
rs2378945 14 31831584 NUBPL G/A A Intronic (16)
rs717117 11 57127131 OR5BP1P||LRRC55 A/G G Intronic (14)
rs1532269 5 32018735 PDZD2 C/G G Intronic (17)
rs4651370 1 187269960 PLA2G4A||FDPSL1 A/T A Intronic (16)
rs854547 7 95294544 PPP1R9A A/G G 3’UTR (15)
rs854548 7 95296508 PPP1R9A||PON1 A/G A Downstream (15)
rs10945919 6 163765645 QKI||LOC728275 A/G G Intronic (15)
rs437943 4 35370476 CENTD1 A/G G Upstream (15)
rs3794271 12 20707159 SLCO1C1 C/T C Intronic (14)
rs4694890 4 48224250 TEC A/C C Intronic (17)
rs1447722 3 139835611 TRMT112P5 C/G C Intergenic (16)October 2021 | Volume 12 | ArtSNP, single nucleotide polymorphism; MAF, minor allele frequency; UTR, untranslated region.
References: (14–17).icle 672255
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was performed using the Kaluza software (Beckman Coulter,
v.1.3). In order to reduce inter-experimental noise and increase
statistical power, cell count analysis was performed by
calculating parental and grandparental percentages, which were
defined as the percentage of a certain cell type within the cell-
populations one or two levels higher in the hierarchical
definitions of cell sub-populations (34). Detailed laboratory
protocols for cell isolation, reagents, gating and flow cytometry
analysis have been reported elsewhere (35) and the accession
number for the raw flow cytometry data and analyzed data files
are available upon request to the authors (http://hfgp.bbmri.nl).
A proteomic analysis was also performed in serum and plasma
samples from the 500FG cohort. Circulating proteins were
measured using the commercially Olink® Inflammation panel
(Olink, Sweden) that resulted in the measurement of 103
different biomarkers (Supplementary Table 3). Proteins levels
were expressed on a log2-scale as normalized protein expression
values, and normalized using bridging samples to correct for
batch variation. Considering the number of proteins (n=103)
and cell populations (n=91) tested, P-values of 0.00049 and
0.00055 were set as significant thresholds for the proteomic
and cell-level variation analysis, respectively.RESULTS
A total of 1361 anti-TNF patients were included in the discovery
population. The mean age of the RA patients was 52±14 and they
showed a female/male ratio of 3.4 (1050/310). Sixty-seven
percent of the RA patients were positive for RF and 64% had
anti-citrullinated protein antibodies (ACPA). The median
disease duration was of 12.92 years and the disease activity
score 28 (DAS28CRP) calculated at patient recruitment was of
5.91 (Table 1).
Association of GWAS-Identified SNPs With
Response to Anti-TNF Drugs
All SNPs were in Hardy-Weinberg equilibrium in the control
group (responders according to EULAR response criteria;
P>0.001) and showed a high genotyping call rate (>90%) with
the exception of the LINC01387rs4411591 SNP that was excluded
from the statistical analysis. The overall linear regression analysis
of the discovery cohort including 1361 RA patients treated with
TNFi showed that the MAFBrs6028945, MAFBrs6071980,
LINC02549rs7767069, and LRRC55rs717117 SNPs had an overall
significant effect on the response to TNFi at P<0.05 level
(ORDominant=0.81, 95%CI 0.68-0.97, P=0.020; per-allele
OR=0.83, 95%CI 0.72-0.97, P=0.020; per-allele OR=0.85, 95%
CI 0.76-0.96, P=0.008; per-allele OR=0.76, 95%CI 0.60-0.97,
P=0.026; Table 3). Importantly, the meta-analysis of the
discovery and replication cohorts confirmed the overall
association of the LINC02549rs7767069 SNP with lower DAS28
improvement that remained significant after multiple testing
correction (per-allele ORMeta=0.83, 95%CI 0.76-0.91,
PMeta=0.000077; PHet=0.61; Table 4). Although it did notFrontiers in Immunology | www.frontiersin.org 5survive multiple testing correction, the meta-analysis also
showed a potentially interesting overall associations for the
MAFBrs6071980 SNP with less DAS28 improvement (per-allele
ORMeta_rs6071980 = 0.85, 95%CI 0.76-0.95, P=0.0059;
PHet=0.63; Table 4).
A RF-stratified analysis showed a RF-specific association for
the LRRC55rs717117 SNP with response to TNFi that remained
statistically significant after correction for multiple testing in the
discovery population. Thus, RF-positive RA patients carrying the
LRRC55rs717117G allele additively decreased the drop in DAS28
(per-allele OR=0.54, 95%CI 0.39–0.74, P=0.00012) whereas RF-
negative RA patients showed an opposite but not statistically
significant effect (per-allele OR=1.52, 95%CI 0.96–2.42, P=0.07;
PInteraction=0.00028; Table 3). Interestingly, the meta-analysis of
our data with those from the DREAM registry including 2067 RA
patients confirmed the RF-specific effect of this SNP to modulate
the response to anti-TNF drugs (per-allele ORMeta_RF+=0.67, 95%
CI 0.54-0.84, PMeta=0.00058; PHet=0.06 and per-allele
ORMeta_RF-=1.38, 95%CI 0.94-2.02, P=0.10; PHet=0.45;
PInteraction=0.00028; Table 4). Although it did not survive
multiple testing, the meta-analysis also showed potentially
interesting RF-specific association for the CNTN5rs1813443 SNP
with a decreased drop in DAS28 (ORMeta_rs1813443_RF+=0.81, 95%
CI 0.70-0.94, P=0.0059; PHet=0.69 and ORMeta_rs1813443_RF-=1.00,
95%CI 0.79-1.27, P=0.99; PHet=0.12; PInteraction=0.032; Table 4).
Functional Characterization of the Most
Interesting Findings
Considering these results, we attempted to shed some light into the
functional consequences of the overall or RF-specific effects of the
LINC02549rs7767069, LRRC55rs717117, MAFBrs6071980 and
CNTN5rs1813443 SNPs to modulate the response to TNFi.
Interestingly, our functional experiments showed that, when
considering the total number of leukocytes as reference, the
LINC02549rs7767069 polymorphism significantly correlated with
increased numbers of CD45RO+CD45RA+ T cells in blood
(P=0.00047; Figure 1A). Subjects carrying the LINC02549rs7767069T
allele (associated with poor response to TNFi in RA patients) had
significantly increased numbers of CD45RO+CD45RA+ T cells
(P=0.000025), which suggested that this genetic marker might
influence the response to TNFi by mediating the number of this
specific T cell subset in blood and, thereby contribute to
inflammation. In addition, we observed that those subjects carrying
two copies of the LINC02549rs7767069T allele showed significantly
increased serum levels of soluble scavenger receptors CD5 and CD6
when compared with those carrying the A/T or A/A genotypes
(P=0.00037 and P=0.00041; Figures 1B, C). These results also
suggested a functional role of the LINC02549rs7767069 SNP in RA
likely through the CD5/CD6-mediated modulation of T cells and
certain subsets of B cells that control multiple processes including
cellularadhesionandmigrationacross endothelial andepithelial cells,
antigen presentation by B cells and the subsequent proliferation of
T cells.
Furthermore, although we could not stratify our functional
analyses by RF status because of the healthy nature of the blood
donors, we found that carriers of the LRRC55rs717117G alleleOctober 2021 | Volume 12 | Article 672255
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stimulation of PBMCs with either B. burgdorferi (P=0.00046;
Figure 2A) or E. coli (P=0.00044; Figure 2B), which suggested an
implication of the LRRC55 locus in the modulation of the
response to TNFi by regulating IL6 production and likely IL6-
mediated T cell differentiation into effector Th2 cells. Functional
data from Haploreg also showed that the LRRC55rs717117 variant
correlates with mRNA P2RX3 expression levels, a well-known
gene involved in controlling T cell proliferation. Finally, our
functional experiments revealed that carriers of the
MAFBrs6071980
C allele showed decreased levels of Chemokine
(C-C motif) ligand 23 (CCL23; P=0.0060; Figure 3A) and
increased levels of serum Fibroblast growth factor 19 (FGF-19;
P=0.0034; Figure 3B). Whereas FGF-19 protein modulates
inflammation by mediating IL6 production, CCL23 has been
implicated in monocyte recruitment during inflammation and it
has been previously shown to positively correlate with drop in
DAS28 after treatment with TNFi. Although the effect of the
MAFB SNP to modulate either serum FGF-19 or CCL23 levels
did not remain significant after correction for multiple testing,
these results might indicate a weak, but still functional, effect of
the MAFB locus in modulating response to anti-TNF drugs.Frontiers in Immunology | www.frontiersin.org 6DISCUSSION
Although treatment of RA patients using monoclonal anti-TNF
drugs has been a particularly successful approach to control
inflammation and to prevent joint destruction and the
appearance of bone erosions, non-responsiveness is prevalent
and no effective biomarkers for drug response prediction have
been consistently identified (36). This comprehensive validation
study aimed at confirming the association of GWAS-identified
variants with response to TNFi and to shed some light into the
biological mechanisms underlying the most interesting
associations. For that purpose, we conducted a two-stage case
control study including 2067 RA patients treated with anti-TNF
drugs ascertained through the REPAIR consortium but also
DANBIO and DREAM registries. The most significant result
was the overall association of the LINC02549rs7767069 SNP with a
poor response to anti-TNF drugs. The meta-analysis of the
discovery and replication cohorts showed that each copy of
the LINC02549rs7767069T allele significantly decreased the
improvement in DAS28 by 17% after the treatment with a
TNFi. Importantly, the association of the LINC02549rs7767069
variant with poor response to TNFi was significant in the twoTABLE 3 | Overall and RF-specific associations of selected polymorphisms and response to anti-TNF drugs (DDAS28) in the REPAIR consortium.
Gene SNP ID Effect allele Overall RF-positive patients RF-negative patients PInteraction
REPAIR+DANBIO (n=1361) REPAIR+DANBIO (n=721) REPAIR+DANBIO (n=347)
OR (95% CI)d P OR (95% CI)d P OR (95% CI)d P
ALPL rs885813 T 0.96 (0.86-1.07) 0.48 1.06 (0.91-1.22) 0.47 0.80 (0.65-0.99) 0.040 0.13
ALPL rs885814 T 0.96 (0.85-1.07) 0.45 0.91 (0.78-1.06) 0.24 1.18 (0.95-1.47) 0.14 0.08
CNTN5 rs1813443 C 0.97 (0.84-1.13)† 0.72 0.79 (0.65-0.97)† 0.023 1.14 (0.86-1.53)† 0.34 0.032
CREBBP rs8046065 T 1.01 (0.87-1.19) 0.85 1.18 (0.96-1.45) 0.11 0.82 (0.60-1.10) 0.19 0.07
CST2||CST5 rs6138150 C 1.06 (0.92-1.22) 0.40 1.04 (0.87-1.26) 0.66 1.01 (0.77-1.32) 0.96 0.72
HSPEP1||MAFB rs6028945 T 0.81 (0.68-0.97)† 0.020 0.89 (0.70-1.21)† 0.31 0.78 (0.53-1.09)† 0.14 0.57
HSPEP1||MAFB rs6071980 C 0.83 (0.72-0.97) 0.020 0.85 (0.70-1.03) 0.10 0.81 (0.58-1.14) 0.23 0.73
IFNK||C9orf72 rs3849942 T 1.02 (0.90-1.15) 0.74 0.93 (0.79-1.10) 0.39 1.21 (0.95-1.55) 0.13 0.27
LASS6 rs13393173 A 1.10 (0.96-1.25) 0.19 1.08 (0.91-1.28) 0.41 1.18 (0.89-1.55) 0.25 0.48
LMO4||PKN2 rs983332 A 1.12 (0.97-1.29) 0.11 1.14 (0.95-1.38) 0.16 1.07 (0.84-1.38) 0.58 0.68
C9orf47 rs1875620 A 0.94 (0.84-104) 0.24 0.93 (0.81-1.08) 0.34 0.80 (0.65-0.99) 0.037 0.29
CBLN2|| LOC100132647 rs1539909 A 0.96 (0.81-1.13) 0.62 0.88 (0.70-1.10) 0.27 0.84 (0.61-1.16) 0.29 1.00
LOC102723883||LINC02549 rs7767069 T 0.85 (0.76-0.96) 0.008 0.91 (0.78-1.08) 0.28 0.81 (0.65-1.01) 0.058 0.11
LOC107986770||ETV1 rs1568885 T 0.67 (0.40-1.10)§ 0.11 0.84 (0.42-1.66)§ 0.61 0.44 (0.20-0.98)§ 0.046 0.23
LOC400456||LOC100132798 rs10520789 A 1.03 (0.86-1.22) 0.76 1.14 (0.90-1.44) 0.29 1.01 (0.72-1.41) 0.97 0.48
MAP2K6||KCNJ16 rs11870477 C 1.07 (0.91-1.25) 0.42 0.92 (0.74-1.14) 0.46 1.18 (0.85-1.65) 0.33 0.13
NUBPL rs2378945 A 1.02 (0.91-1.13) 0.79 1.06 (0.91-1.24) 0.44 0.97 (0.79-1.20) 0.81 0.41
OR5BP1P||LRRC55 rs717117 G 0.76 (0.60-0.97) 0.026 0.54 (0.39-0.74) 0.00012 1.52 (0.96-2.42) 0.07 0.00028
PDZD2 rs1532269 G 1.01 (0.88-1.16) 0.86 1.03 (0.89-1.20) 0.68 1.02 (0.82-1.26) 0.87 0.95
PLA2G4A||FDPSL1 rs4651370 A 1.05 (0.90-1.23) 0.53 1.09 (0.88-1.35) 0.42 0.92 (0.69-1.24) 0.60 0.15
PPP1R9A rs854547 G 1.00 (0.89-1.11) 0.95 1.03 (0.89-1.19) 0.71 0.92 (0.74-1.14) 0.43 0.46
PPP1R9A||PON1 rs854548 A 1.01 (0.89-1.15) 0.89 1.04 (0.87-1.24) 0.67 0.85 (0.66-1.10) 0.22 0.39
QKI||LOC728275 rs10945919 G 0.88 (0.76-1.03)† 0.11 0.79 (0.64-0.97)† 0.027 1.03 (0.77-1.38)† 0.85 0.14
SEC63P3 rs437943 G 1.10 (0.95-1.28)† 0.21 0.98 (0.80-1.20)† 0.82 1.37 (1.02-1.85)† 0.037 0.25
SLCO1C1 rs3794271 C 0.95 (0.85-1.07) 0.39 0.96 (0.82-1.11) 0.57 1.02 (0.82-1.27) 0.87 0.34
TEC rs4694890 C 0.96 (0.86-1.07) 0.42 1.01 (0.87-1.17) 0.86 0.84 (0.67-1.05) 0.12 0.37
TRMT112P5 rs1447722 C 1.03 (0.92-1.15) 0.61 1.01 (0.87-1.18) 0.85 1.08 (0.87-1.35) 0.48 0.81October 2021 | Volume 12 | ArtiSNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.
Data on RF was available in 1069 RA patients. Estimates were adjusted for age, sex and country of origin. P < 0.05 in bold.
dEstimates calculated according to a log-additive model of inheritance.
†Estimates calculated according to a dominant model of inheritance.
§Estimates calculated according to a recessive model of inheritance.cle 672255
Sánchez-Maldonado et al. GWAS Markers for TNFi Responsepopulations analyzed and remained significant after correction
for multiple testing, which confirmed a role of the LINC02549
locus in the modulation of response to anti-TNF drugs.
LINC02549 (Long Intergenic Protein Coding RNA 2549) is
an RNA gene that is affiliated with the lncRNA class, which
represents a large proportion of the human transcriptome.
LINC02549 maps to chromosome 6 and it is expressed in
resting T cells and CD4 activated T cells. Although its function
is still largely unknown, our data suggest that it might exert a role
in determining the number of circulating CD45RO+CD45RA+ T
cells, which are a subset of cells frequently found in the synovial
fluid of both chronic arthritis (37) and RA patients (38).
According to the results of Koch et al. (1990), CD45RA+
CD45RO+ T lymphocytes are mostly detected in perivascular
regions, which suggest that these lymphocytes might access the
RA synovial tissue via the synovial vasculature (38) and that,
once there, they could play a role in promoting synovial tissue
inflammation mainly by the induction of memory immune
responses. Therefore, it seems to be plausible to suggest that
the negative impact of the LINC02549rs7767069 SNP on the
response to TNFi might be mediated by its role in modulating
numbers of CD45RA+CD45RO+ T lymphocytes that could
migrate to the synovial tissue and promote inflammatory
responses and, thereby hamper the control of inflammation
during treatment with anti-TNF drugs. In support of this
hypothesis, we found that carriers of two copies of the
LINC02549rs7767069T allele also showed significantly increased
levels of soluble scavenger receptors CD5 and CD6 (sCD5 and
sCD6) in serum that are proteins highly expressed in regulatoryFrontiers in Immunology | www.frontiersin.org 7T cells and a specific subset of B cells (CD5+ or B1a) (39).
Although the origin of these soluble scavenger receptors in RA is
poorly understood, it has been suggested that they are shed in the
serum by proteases from the surface of activated lymphocytes
that subsequently infiltrate synovium structures (40). In fact,
increased serum levels of sCD5 and sCD6 has been found in
subjects diagnosed with RA (41–44) but also other autoimmune
diseases such as primary Sjögren’s syndrome (42, 45, 46),
systemic inflammatory response syndrome (47), multiple
sclerosis (44) or dermatitis (48). Although the functional role
of both soluble scavengers in autoimmune diseases is still under
investigation, it is well established that sCD5 and sCD6 are
regulators of T cell functions and induce autoreactivity. It is
known that they are required for the initiation, differentiation
and maintenance of T cell immune responses (49, 50) but also T
cell migration and extravasation to the synovial tissue (51).
Furthermore, it has been reported that both sCD5 and sCD6
are involved in the modulation of TCR and BCR signaling and
determinate T- and B-cell survival (52) and Th17 differentiation
(53, 54). Furthermore, clinical trials using humanized anti-CD6
mAbs have provided valuable information regarding the
potential targeting of CD6 for the treatment of RA but also
psoriasis and potentially other T cell–driven autoimmune
diseases (55–57). Recent investigations have also suggested that
genetic alterations within the CD6 gene associated with clinical
outcome of several autoimmune diseases (44, 58) and correlated
with the response to TNFi (59), which pointed to a role of these
soluble scavenger receptors in modulating response to anti-TNF
drugs. Considering these findings, we hypothesize that, besidesTABLE 4 | Overall and RF-specific meta-analysis of the CNTN5rs1813443, MAFBrs607198, LINCO2549rs7767069 and LRRC55rs717117 polymorphisms and response to anti-
TNF drugs.
Gene SNP ID Effect allele Overall Overall Meta-analysis (n=2067) PHeterogeneity
REPAIR+DANBIO (n=1361) DREAM (n=706)
OR (95% CI)d P OR (95% CI)d P OR (95% CI)d P
CNTN5 rs1813443 C 0.97 (0.84-1.13)† 0.72 0.82 (0.68-1.00)† 0.046 0.91 (0.81-1.03)† 0.12 0.18
HSPEP1||MAFB rs6071980 C 0.83 (0.72-0.97) 0.020 0.88 (0.73-1.06) 0.18 0.85 (0.76-0.95) 0.0059 0.63
LOC102723883||LINC02549 rs7767069 T 0.85 (0.76-0.96) 0.008 0.80 (0.70-0.93) 0.004 0.83 (0.76-0.91) 0.00007 0.61
OR5BP1P||LRRC55 rs717117 G 0.76 (0.60-0.97) 0.026 0.89 (0.67-1.20) 0.46 0.81 (0.67-0.98) 0.026 0.41
Effect allele RF-positive patients RF-positive patients RF-positive patients
REPAIR+DANBIO (n=721) DREAM (n=532) Meta-analysis (n=1253)
Gene SNP ID OR (95% CI)d P OR (95% CI)d P OR (95% CI)d P PHeterogeneity
CNTN5 rs1813443 C 0.79 (0.65-0.97)† 0.023 0.84 (0.67-1.04)† 0.12 0.81 (0.70-0.94)† 0.0059 0.69
HSPEP1||MAFB rs6071980 C 0.85 (0.70-1.03) 0.10 0.85 (0.69-1.04) 0.11 0.85 (0.73-0.98) 0.023 1.00
LOC102723883||LINC02549 rs7767069 T 0.91 (0.78-1.08) 0.28 0.82 (0.69-0.97) 0.022 0.87 (0.77-0.97) 0.016 0.39
OR5BP1P||LRRC55 rs717117 G 0.54 (0.39-0.74) 0.00012 0.83 (0.60-1.15) 0.28 0.67 (0.54-0.84) 0.00058 0.06
Effect allele RF-negative patients RF-negative patients RF-positive patients
REPAIR+DANBIO (n=347) DREAM (n=154) Meta-analysis (n=501)
Gene SNP ID OR (95% CI)d P OR (95% CI)d P OR (95% CI)d P PHeterogeneity
CNTN5 rs1813443 C 1.14 (0.86-1.53)† 0.34 0.76 (0.50-1.16)† 0.20 1.00 (0.79-1.27)† 0.99 0.12
HSPEP1||MAFB rs6071980 C 0.81 (0.58-1.14) 0.23 1.10 (0.71-1.71) 0.67 0.91 (0.69-1.19) 0.48 0.28
LOC102723883||LINC02549 rs7767069 T 0.81 (0.65-1.01) 0.058 0.76 (0.55-1.04) 0.08 0.79 (0.66-0.95) 0.012 0.75
OR5BP1P||LRRC55 rs717117 G 1.52 (0.96-2.42) 0.07 1.10 (0.55-2.19) 0.80 1.38 (0.94-2.02) 0.10 0.45October 2021 | Volume 12 | ASNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.
Response to anti-TNF defined as DDAS28. Data on RF was available in 1068 and RA patients in the discovery (REPAIR+DANBIO) and replication cohorts (DREAM).
Association estimates were adjusted for age, sex and country of origin in the discovery cohort and age and sex in the replication cohort (all Dutch patients). P < 0.05 in bold.
dEstimates calculated according to a log-additive model of inheritance.
†Estimates calculated according to a dominant model of inheritance.rticle 672255
Sánchez-Maldonado et al. GWAS Markers for TNFi Responseits effect on modulating number of the CD45RA+CD45RO+ T
lymphocytes, the LINC02549rs7767069 SNP might negatively
influence the response to anti-TNF drugs by stimulatingFrontiers in Immunology | www.frontiersin.org 8directly or indirectly the production of sCD5 and sCD6 and
thereby inducing long-term T cell-mediated immune responses.
Another interesting result that remained significant after
correction for multiple testing was the RF-specific association
of the LRRC55rs717117 SNP with lower changes in DAS28 after the
treatment with TNFi. The meta-analysis of the discovery and
replication cohorts showed that RF-positive patients carrying the
LRRC55rs717117G allele have a significantly decreased drop in
DAS28 after treatment with a TNFi, whereas an opposite but not
statistically significant effect was observed in RF-negative RA
patients. Noticeably, functional experiments showed that, after
stimulation of PBMCs from healthy subjects with B. burgdorferi
and E. coli bacteria, carriers of the LRRC55rs717117G allele showed
significantly decreased production of IL6 when compared toA
B
C
FIGURE 1 | Correlation of the LINC02549rs7767069 polymorphism with
absolute numbers of CD45RO+CD45RA+ T cells in blood (A) and serum
levels of soluble scavenger receptors CD5 (B) and CD6 (C).A
B
FIGURE 2 | Correlation of the LRRC55rs717117G allele and levels of IL6 after
stimulation of PBMCs either with B. burgdorferi (A) or E. coli (B).October 2021 | Volume 12 | Article 672255
Sánchez-Maldonado et al. GWAS Markers for TNFi Responsethose carrying the most common genotype. Although functional
experiments could not be stratified by RF because of the healthy
nature of blood donors, these results suggested a role of the
LRRC55 locus in modulating IL6-mediated immune responses.
On the other hand, functional data from Haploreg also suggested
an implication of the LRRC55rs717117 variant in controlling
P2RX3-mediated T cell proliferation.
LRRC55 gene maps on chromosome 11 and it encodes for the
leucine-rich repeat-containing protein 55, a protein that belongs to
the LRRC superfamily that include hundreds of proteins mainly
expressed in brain. Several LRRC proteins have been linked to the
regulation of ion channels (60) but it has been also demonstrated
that LRRC proteins are also implicated in modulating immune
responses against bacterial pathogens (61) and modulate cellFrontiers in Immunology | www.frontiersin.org 9trafficking of membrane receptors such as toll-like receptors
(62). Although the interplay between LRRC55 and IL6 has not
been demonstrated, our experimental data suggest that the
LRRC55rs717117 SNP modulates IL6 production in response to
bacteria and, therefore, might be involved in other IL6-dependent
immune processes that could worsen the response to TNFi.
It is widely known that IL6 can induce both anti-
inflammatory and pro-inflammatory immune responses, which
depend entirely on the signalling pathway triggered. Whereas
anti-inflammatory responses are mostly mediated by the classic
signalling cascade (through binding to the transmembrane
IL6 receptor), pro-inflammatory responses and chronic
inflammation are mediated by trans-signalling (through
binding to the soluble IL6 receptor) or by the interaction of
IL6R with gp130 (63, 64). Considering our functional data, it is
conceivable to suggest that the LRRC55rs717117 SNP might affect
the response to TNFi by decreasing IL6 production and thus
inhibiting the classical IL6-dependent anti-inflammatory
pathway and dysregulating pro-inflammatory responses. In
support of this hypothesis, several mouse models have shown
that the activation of the IL6 classic signaling pathway is essential
for the activation of STAT3-mediated signaling pathways which
reduce inflammation and induce the regeneration of the affected
tissues (65). In addition, it has been reported that IL6 is one of
the earliest factors that trigger the differentiation of naive T cells
into effector Th2 cells in vitro and that, when absent, aggravates
the development of the inflammatory processes (64).
Finally, although the genetic association of theMAFBrs6071980
SNP with lower response to TNFi did not remain significant after
correction for multiple testing, we found that the MAFBrs6071980
SNP correlated with higher levels of serum FGF-19 and
decreased levels of CCL23. Given that FGF-19 is a master
protein involved in the inhibition of intestinal inflammation
(66, 67) and CCL23 has been positively correlated with the
DAS28 score in RA patients (68), we think that it would worth
to investigate more in detail the impact of this SNP on drug
response in future studies. In addition, it might be interesting to
further analyze the weak association of the CNTN5rs1813443 SNP
with poor response to TNFi. However, given that we could not
find any significant impact of this marker on immune responses,
blood cell counts or serum inflammatory proteins or steroid
hormones, we are prone to think that this SNP might not have a
relevant role in modulating response to TNFi.
This study has both strengths and weaknesses. Among the
strengths we can highlight the use of large and well-characterized
RA patient populations that allowed the development of a well-
powered overall association analysis but also to investigate the
effect modification by RF status. Overall, we had 80% of power to
detect an OR of 1.18 (a=0.00089) for a SNP with a frequency of
0.25. On the other hand, it is worth mentioning the
comprehensive analysis of the functional effect of the most
interesting genetic variants on modulating immune responses,
which was performed using a large sample size for this kind of
studies. We analysed cQTL and hQTL data but also counts of 91
blood-derived cell populations and serum levels of 103
immunological proteins. An important limitation of this studyA
B
FIGURE 3 | orrelation of the MAFBrs6071980C allele with serum levels of
CCL23 (A) and FGF-19 proteins (B).October 2021 | Volume 12 | Article 672255
Sánchez-Maldonado et al. GWAS Markers for TNFi Responsewas the impossibility to adjust linear regression analyses for
potential confounding factors including concomitant treatments
that might influence the response to TNFi. In addition, given the
healthy nature of the subjects included in the HFGP cohort, we
could not control our functional experiments by RF status.
In conclusion, this study validates the overall or RF-specific
association of LINC02549 and LRRC55 loci with the response to
TNFi and provides new insights into the functional role of these
polymorphisms in modulating immune responses and response
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